Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.

You may also be interested in...



GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain

British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.

GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain

British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.

Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus

Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

PS065632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel